Claims for Patent: 7,314,636

Summary for Patent: 7,314,636

Title:	Biodegradable injectable implants containing glycolic acid
Abstract:	This invention is directed to the field of medical implants, and more specifically to biodegradable injectable implants and their methods of manufacture and use. The injectable implants disclosed herein comprise glycolic acid and bio-compatible/bio-absorbable polymeric particles containing a polymer of lactic acid. The particles are small enough to be injected through a needle but large enough to avoid engulfment by macrophages. The injectables of this invention may be in a pre-activated solid form or an activated form (e.g., injectable suspension or emulsion).
Inventor(s):	Caseres; Crisoforo Peralta (Mexico City, MX), de Lagarde; Daniel Leon (Mexico City, MX)
Assignee:	Medgraft Microtech, Inc. (Valencia, ES)
Application Number:	10/186,183
Patent Claims:	1. A biodegradable, injectable implant comprising glycolic acid monomer and particles comprised of a polymer comprising lactic acid repeats units, wherein the particles have a diameter of from about 20 .mu. to about 120 .mu. and are suspended in a pharmaceutically accentable carrier, and the glycolic acid monomer is present in a concentration of from about 1.8 mcg to about 18.2 mcg glycolic acid monomer per 100 ml of the pharmaceutically acceptable carrier. 2. The implant of claim 1, wherein the particles have a diameter of from about 40.mu. to about 80.mu.. 3. The implant of claim 2, wherein the particles have a mean diameter of from about 50.mu. to about 70.mu.. 4. The implant of claim 1, wherein the pharmaceutically acceptable carrier comprises water, saline, starch, hydrogel, polyvinylpyrrolidone, polysaccharide, hyaluronic acid ester, or plasma. 5. The implant of claim 1, wherein the polymer is present in a concentration of from about 30 mg to about 40 mg of polymer per 100 ml of the pharmaceutically acceptable carrier. 6. The implant of claim 5, wherein the polymer is present in a concentration of from about 35 mg to about 38 mg per 100 ml of the pharmaceutically acceptable carrier. 7. The implant of claim 1, wherein the glycolic acid monomer is present in a concentration of from about 11 mcg to 14 mcg per 100 ml of the pharmaceutically acceptable carrier. 8. The implant of claim 1 further comprising a gelling agent. 9. The implant of claim 8, wherein the gelling agent comprises a cellulose derivative or a pharmaceutically acceptable acid or ester. 10. The implant of claim 9, wherein the cellulose derivative comprises hydroxypropylmethylcellulose or carboxymethylcellulose. 11. The implant of claim 9, wherein the pharmaceutically acceptable acid or ester is selected from the group consisting of a synthetic hyaluronic acid, a lactic acid ester, sodium carmellose, and a caproic acid ester. 12. The implant of claim 1 further comprising a surfactant. 13. The implant of claim 12, wherein the surfactant comprises a polyoxyethylene sorbitan, a polysorbate or pluronic acid. 14. The implant of claim 13, wherein the polyoxyethylene sorbitan comprises polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, polyoxyethylene sarbitan monopalmitate, or polyoxyethylene sorbitan monolaurate. 15. The implant of claim 1, wherein the polymer comprises a homopolymer of lactic acid. 16. The implant of claim 15, wherein the polymer comprises poly-1-lactic acid or poly-d,1-lactic acid. 17. The implant of claim 1, wherein the polymer comprises a co-polymer of lactic acid. 18. The implant of claim 17, wherein the polymer comprises a co-polymer of lactic acid and glycolic acid. 19. The implant of claim 17, wherein the polymer comprises repeat units capable of forming crosslinks. 20. The implant of claim 17, wherein the polymer comprises at least one lactone repeat unit. 21. The implant of claim 1, wherein the polymer has an intrinsic viscosity of from about 3.5 to about 3.8 dl/g. 22. The implant of claim 1, wherein the polymer has a molecular weight of from about 150,000 to about 220,000 Daltons. 23. The implant of claim 22, wherein the polymer has a molecular weight of from about 165,000 to 180,000 Daltons. 24. The implant of claim 23, wherein the polymer has a melting point ranging from about 170 to about 200.degree. C. 25. The implant of claim 1 further comprising a cryoprotecting agent. 26. The implant of claim 25, wherein the cryoprotecting agent comprises d-mannitol, lactose, sucrose, fructose, a sugar, a carbohydrate, or dextran. 27. The implant of claim 1 further comprising a buffering agent. 28. The implant of claim 27, wherein the buffering agent comprises a phosphate buffer or a citrate buffer. 29. The implant of claim 1, wherein the implant is ma vial in the form of a sterile suspension. 30. The implant of claim 1, wherein the implant further comprises particles comprised of a polymer comprising lactic acid repeats units and wherein the implant is formed by the suspension of a lyophilized powder of the particles in the pharmaceutically acceptable carrier. 31. The implant of claim 30, wherein from about 0.002% to about 0.02% by weight of the implant is glycolic acid monomer. 32. The implant of claim 31, wherein from about 0.01% to about 0.02% by weight of the implant is glycolic acid monomer. 33. The implant of claim 30, wherein the lyophilized powder comprises from about 36% to about 45% polymer by weight. 34. The implant of claim 33, wherein the lyophilized powder comprises from about 40% to about 41% polymer by weight. 35. The implant of claim 1, wherein the implant has been sterilized by gamma or E-beam irradiation or exposure to ethylene oxide gas. 36. The implant of claim 1, further comprising a medicament. 37. The implant of claim 36, wherein the medicament comprises a peptide, a tissue regeneration agent, an anesthetic, an antibiotic, a steroid, fibronectin, a cytokine, a growth factor, an analgesic, an antiseptic, alpha-, beta, or gamma-interferon, erythroietin, glucagons, calcitonin, heparin, interleukin-1, interleukin-2, filgrastim, cDNA, DNA, PROTEINS, PEPTIDES, HGH, luteinizing hormone, atrial natriuretic factor, Factor VIII, Factor IX, or follicle-stimulating hormone. 38. The implant of claim 37, wherein the medicament comprises an anesthetic which is selected from the group consisting of lidocaine, xylocaine, novocaine, benzocaine, prilocaine, ripivacaine, and propofol. 39. A biodegradable, injectable implant comprising glycolic acid monomer and particles comprised of polylactic acid, wherein the particles have a mean diameter of from about 40.mu. to about 80.mu. and are suspended in a pharmaceutically acceptable carrier, and the glycolic acid monomer is present in a concentration of from about 1.8 mcg to about 18.2 mcg glycolic acid monomer per 100 ml of the pharmaceutically acceptable carrier. 40. The implant of claim 39, wherein the particles have a mean diameter of from about 55.mu., to about 65.mu.. 41. The implant of claim 39, wherein the polylactic acid comprises poly-1-lactic acid or poly-d,1-lactic acid, or co-polylactide-polyglycolide. 42. The implant of claim 39, wherein the polylactic acid has an intrinsic viscosity of from about 3.6 dl/g to about 3.8 dl/g. 43. The implant of claim 39, wherein the polylactic acid has a molecular weight as determined by viscosity from about 150,000 to about 180,000 Daltons. 44. The implant of claim 39, wherein the pharmaceutically acceptable carrier comprises water. 45. The implant of claim 44, wherein the pharmaceutically acceptable carrier comprises saline, starch, hydrogel, polyvinylpyrrolidone, polysaccharide, hyaluronic acid ester, or plasma. 46. The implant of claim 44, wherein the polylactic acid is present in a concentration of from about 30 mg to about 40 mg of polymer per 100 ml of the pharmaceutically acceptable carrier. 47. The implant of claim 39 further comprising a gelling agent. 48. The implant of claim 47, wherein the gelling agent comprises a cellulose derivative or a pharmaceutically acceptable acid or ester. 49. The implant of claim 48, wherein the cellulose derivative comprises hydroxypropylmethylcellulose or carboxymethylcellulose. 50. The implant of claim 48, wherein the pharmaceutically acceptable acid or ester comprises a synthetic hyaluronic acid, a lactic acid ester, sodium carmellose, or a caproic acid ester. 51. The implant of claim 39 further comprising a surfactant. 52. The implant of claim 51, wherein the surfactant comprises a polyoxyethylene sorbitan, a polysorbate or pluronic acid. 53. The implant of claim 52, wherein the polyoxyethylene sorbitan comprises polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, polyoxyethylene sorbitan monopalmitate, or polyoxyethylene sorbitan monolaurate. 54. The implant of claim 39 further comprising a cryoprotecting agent. 55. The implant of claim 54, wherein the cryoprotecting agent comprises d-mannitol, lactose, sucrose, fructose, or dextran. 56. The implant of claim 39 further comprising a buffering agent. 57. The implant of claim 56, wherein the buffering agent comprises a sodium phosphate or a citrate buffer. 58. The implant of claim 39, wherein the implant is in a vial in the form of a sterile suspension. 59. The implant of claim 39, wherein the implant comprises particles comprised of a polymer comprising lactic acid repeats units and wherein the implant is formed by the suspension of a lyophilized powder of the particles in a pharmaceutically acceptable carrier. 60. The implant of claim 59, wherein from about 0.002% to about 0.02% by weight of the implant is glycolic acid monomer. 61. The implant of claim 60, wherein the lyophilized powder comprises from about 36% to about 45% polymer by weight. 62. The implant of claim 39 further comprising a medicament selected from the group consisting of an anesthetic, a peptide, a tissue regeneration agent, an antibiotic, a steroid, fibronectin, a cytokine, a growth factor, an analgesic, an antiseptic, alpha-, beta, or gamma-interferon, erythroietin, glucagons, calcitonin, heparin, interleukin-1, interleukin-2, filgrastim, cDNA, DNA, PROTEINS, PEPTIDES, HGH, luteinizing hormone, atrial natriuretic factor, Factor VIII, Factor IX, and follicle-stimulating hormone. 63. A biodegradable, injectable implant comprising: a) glycolic acid monomer, wherein the glycolic acid monomer is present in a concentration of from about 12 mcg to about 13 mcg glycolic acid monomer per 100 ml of suspension; b) particles of polylactic acid, wherein the particles have a mean diameter of from about 40.mu. to about 80.mu.; c) a gelling agent; d) a surfactant; e) a cryoprotecting agent; and f) a buffering agent, wherein the implant comprises an aqueous suspension of particles of the polylacticacid. 64. The implant of claim 63, wherein the polylactic acid is poly-1-lactic acid or poly-1,d-lactic acid. 65. The implant of claim 63, wherein the polylactic acid has a molecular weight of from about 160,000 to about 180,000 Daltons. 66. The implant of claim 63, wherein the polylactic acid is present in a concentration of from about 30 mg to about 40 mg of polymer per 100 ml of suspension. 67. The implant of claim 63, wherein the gelling agent comprises hydroxypropylmethylcellulose or carboxymethylcellulose. 68. The implant of claim 63, wherein the surfactant comprises a polyoxyethylene sorbitan. 69. The implant of claim 63, wherein the cryoprotecting agent comprises d-mannitol.

Details for Patent 7,314,636

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2021-06-29
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2021-06-29